

Patients deserve the BEST
Patients deserve the best
CIRCULOGENE begins with a patented Linear In Situ Amplification (LISA) methodology which effectively preserves and extracts fragile RNA. Our use of next-generation sequencing (NGS) and polymerase chain reaction (PCR) instrumentation provides both the breadth of DNA menu and the depth for RNA detection. These two technological advancements are the basis for our best-in-class menu offerings, including TumorClear, ImmunoClear, MSI Complete, and Hereditary Panels.
CIRCULOGENE can complement tissue biopsy as recommended by the International Association for the Study of Lung Cancer (IASLC) for enabling a faster time to treatment, providing the right first-line treatment, and resulting in better patient outcomes.
Each patient’s cancer is unique, understanding the origins and severity of the cancers aids oncologists to personalize the patient’s treatment plan at the time of diagnosis and throughout their cancer journey.
The CIRCULOGENE Best-in-Class Advantage
CIRCULOGENE begins some tests with a proprietary Linear In Situ Amplification (LISA) enrichment process resulting in enhanced cfRNA yields. By eliminating the need for a purification step, CIRCULOGENE overcomes the limitations associated with sample volume requirements. The LISA process preserves and extracts fragile cfRNA, enabling fusions and plasma PD-L1 to be effectively detected.

Combined Methodologies

CIRCULOGENE News
CIRCULOGENE shares results of remarkable rectal cancer study
FOR IMMEDIATE RELEASE CIRCULOGENE shares results of remarkable rectal cancer study Identifying mismatch repair-deficient (MMRd)…
CIRCULOGENE presented plasma PD-L1 data at the American Society for Radiation Oncology (ASTRO) / American Society of Clinical Oncology (ASCO) Multidisciplinary Thoracic Cancers Symposium
FOR IMMEDIATE RELEASE CIRCULOGENE presented plasma PD-L1 data at the American Society for Radiation Oncology (ASTRO)…